Anupam Rasayan scores a global first in ETFA production

Tipsheet Editorial — Thu, 11 Jun 2026 19:59:03 GMT

The company claims a world-first commercialisation of Ethyl trifluoroacetate via continuous flow chemistry, with an addressable market of $500–600M but no revenue number yet.

What’s new

Anupam Rasayan has commercially produced Ethyl trifluoroacetate (ETFA) using continuous flow chemistry, a global first.
ETFA is a fluorinated building block for pharma, life sciences, and performance materials.
The company's process-by-design platform claims safety and scalability advantages over batch processes.

Why it matters

This is a genuine technological differentiator in fluorinated chemicals. Yet with trailing PAT down 11% and EBITDA margin guidance cut 200 bps to 23-24% just weeks ago, the financial translation matters. The addressable market is large but unquantified in revenue terms.

What we’re watching

Any offtake agreements or pilot orders for ETFA.
Revenue contribution in the next 2-3 quarters.
Capacity utilisation and pricing disclosures for the new product.

The full read

Anupam Rasayan has become the first to commercially produce Ethyl trifluoroacetate via continuous flow chemistry, a genuine technological differentiator. The addressable market is $500–600 million, but the press release carries no revenue guidance or order value. That uncertainty matters. Trailing PAT fell 11%, and the company just trimmed EBITDA margin guidance by 200 bps to 23-24%. The innovation is real. Proof will come in orders.

Primary source: BSE · NSE

Anupam Rasayan cuts EBITDA margin guidance by 200 bps, flags consolidation drag

Tipsheet Editorial — Mon, 25 May 2026 18:48:12 GMT

Management now expects an EBITDA margin of 23-24% for FY26, down from 25%, citing the Bliss GVS Pharma consolidation and phasing effects. The ₹14,000 crore order book underpins a 20-30% annual growth outlook.

What’s new

Anupam Rasayan cut its EBITDA margin guidance to 23-24% from 25%.
The order book stands at ₹14,000 crore, providing visibility for 20-30% annual revenue growth over 3-5 years.
The Bliss GVS Pharma acquisition is central to its push for a vertically integrated pharma platform.

Why it matters

A 200 bps margin cut on a call where the headline story was supposed to be growth and integration tells you where the friction is: bringing Bliss GVS in-house is costing near-term profitability. The large order book buys the company time to execute, but the margin trade-off is now explicit.

What we’re watching

The pace of Bliss GVS integration and whether it becomes margin-accretive.
Whether the 20-30% growth rate holds against the newly consolidated base.
Next quarter's margins to confirm the phasing explanation.

The full read

Anupam Rasayan's May 2026 concall delivered two messages. First, growth: a ₹14,000 crore order book that the company says underpins a 20-30% annual revenue growth trajectory for 3-5 years. Second, the cost of that growth: EBITDA margin guidance was cut to 23-24% from 25%, a 200 bps reduction management blamed on consolidating its Bliss GVS Pharma acquisition and normal business phasing. The acquisition is the company's bid to build a vertically integrated pharma CDMO. The margin guidance revision is the market's first hard look at the integration's P&L impact. For now, the order book provides cover. The test is whether the consolidated entity can grow into that book without further margin erosion.

Primary source: BSE · NSE

Anupam Rasayan India Ltd. (ANURAS) — Tipsheet

Anupam Rasayan scores a global first in ETFA production

What’s new

Why it matters

What we’re watching

The full read

Anupam Rasayan cuts EBITDA margin guidance by 200 bps, flags consolidation drag

What’s new

Why it matters

What we’re watching

The full read